Mayfair Advisory Group LLC Has $500,000 Position in Johnson & Johnson (NYSE:JNJ)

by · The Cerbat Gem

Mayfair Advisory Group LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,117 shares of the company’s stock after selling 67 shares during the quarter. Mayfair Advisory Group LLC’s holdings in Johnson & Johnson were worth $500,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Signet Investment Advisory Group Inc. grew its stake in Johnson & Johnson by 1.3% in the third quarter. Signet Investment Advisory Group Inc. now owns 26,192 shares of the company’s stock valued at $4,245,000 after purchasing an additional 340 shares in the last quarter. Burford Brothers Inc. lifted its holdings in shares of Johnson & Johnson by 6.3% during the 3rd quarter. Burford Brothers Inc. now owns 16,569 shares of the company’s stock valued at $2,685,000 after buying an additional 977 shares during the last quarter. Elwood & Goetz Wealth Advisory Group LLC grew its stake in shares of Johnson & Johnson by 110.0% in the 3rd quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,869 shares of the company’s stock valued at $627,000 after buying an additional 2,027 shares in the last quarter. Capital Management Associates Inc increased its holdings in Johnson & Johnson by 121.2% in the third quarter. Capital Management Associates Inc now owns 8,836 shares of the company’s stock worth $1,432,000 after buying an additional 4,842 shares during the last quarter. Finally, Shayne & Jacobs LLC lifted its stake in Johnson & Johnson by 7.9% in the third quarter. Shayne & Jacobs LLC now owns 1,942 shares of the company’s stock valued at $315,000 after acquiring an additional 142 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. The Goldman Sachs Group cut their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. TD Securities decreased their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Get Our Latest Report on JNJ

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $160.88 on Friday. The firm’s 50-day moving average is $163.41 and its 200-day moving average is $155.07. The company has a market cap of $387.28 billion, a price-to-earnings ratio of 23.28, a PEG ratio of 2.90 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period in the previous year, the company posted $2.66 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also